Seeking men and women 70 years of age or younger with untreated mantle cell lymphoma (MCL) to help determine which combination of cancer drugs most effectively treats their (MCL).
We are doing this study because we want to find out if one of these drug combinations is better or worse than the usual approach for MCL. The usual approach is defined as care most people get for MCL. Participants will receive one of the drug combinations over the course of at most six months. After finishing their course of drugs, visits will continue every 2-3 months for 3 years, and then every 6 months until 10 years.
What we're hoping for
This study will help the study doctors find out if these different approaches are better, the same, or worse than the usual approach. Study doctors will be looking to see which treatment combinations shrink patients’ cancer the most.
ClinicalTrials.gov Identifier: NCT04115631